{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335098","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2026-08-05T20:10:04+00:00","discovered_at":"2026-08-05T20:11:00.233951+00:00","generated_at":"2026-08-05T20:11:46.601869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401","bullets":["Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.","Cash and equivalents $78.1M as of June 30, 2026; runway extended through Q3 2027 including $10M Alnylam upfront.","Positive interim data from TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) trials: all evaluable patients showed improvements in hypertrophy and electrical stability.","Additional data and regulatory discussions on pivotal trial plans for TN-201 and TN-401 expected in Q4 2026.","Appointed Eric Hyllengren as CFO effective July 13, 2026; TN-301 Phase 2 trial expected to start 2H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335098","json":"https://secwatch.observer/filing/0001193125-26-335098.json","markdown":"https://secwatch.observer/filing/0001193125-26-335098.md","text":"https://secwatch.observer/filing/0001193125-26-335098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/0001193125-26-335098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:11:46.601869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}